Switching from intravenous to subcutaneous formulation of abatacept: A single-center Italian experience on efficacy and safety

Journal of Rheumatology

Volumn 42, Issue 2, 2015, Pages 193-195

  Reggia, Rossella ^a   Franceschini, Franco ^a   Tincani, Angela ^a   Cavazzana, Ilaria ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Abatacept; Efficacy; Rheumatoid arthritis; Safety; Subcutaneous formulation; Therapy

Indexed keywords

ABATACEPT; CYCLOSPORIN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGED; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; INTRAVENOUS DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; ITALY; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84923171309     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141042     Document Type: Article

References (13)

1. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
2. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011; 70:1826-30.
3. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76.
4. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64.
5. Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis 2012;71:38-44.
6. Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res 2013;65:718-28.
7. Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 2012;71:857-61.
8. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28-38.
9. Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol 2014;66:1987-97.
10. Rakieh C, Conaghan PG. Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis. Ther Clin Risk Manag 2014;10:313-20.
11. Wells AF, Jodat N, Schiff M. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations. Biologics 2014;8:41-55.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol 2014;41:629-39.